Ironwood Pharmaceuticals, Inc. cash flow to debt ratio of 21.25% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ironwood Pharmaceuticals, Inc.'s free cash flow has increased 22.83% from $103.41M last year to $127.01M, signaling increasing performance

Ironwood Pharmaceuticals, Inc.'s debt to equity ratio is -2.45, signaling that the company spent its equity and risk bankruptcy.

Ironwood Pharmaceuticals, Inc.'s debt to equity ratio is -2.45, signaling that the company spent its equity and risk bankruptcy.

Ironwood Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 3.65x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Ironwood Pharmaceuticals, Inc.'s interest coverage ratio of 7.23 indicates that earnings with good margin can cover interest payments on company debt

Ironwood Pharmaceuticals, Inc.'s profit margin has increased (13.22K%) in the last year from 0.25% to 33.36%, signaling increasing performance

Ironwood Pharmaceuticals, Inc.'s short-term assets of $274.18M exceed its short-term liabilities of $242.22M

Ironwood Pharmaceuticals, Inc.'s return on assets of 45.55% is higher than the 5.00% threshold, indicating efficient asset utilization

Ironwood Pharmaceuticals, Inc.'s return on equity of -57.40%, is lower than 15.00%, indicating bad performance

Ironwood Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Ironwood Pharmaceuticals, Inc. had positive net income in 4 out of 5 years, indicating stable and consistent earnings

Ironwood Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Ironwood Pharmaceuticals, Inc. has a free cash flow yield of 19.05%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Ironwood Pharmaceuticals, Inc.'s yearly earnings has increased 2.63K% since last year from $880.00K to $24.02M, signaling increasing performance

Ironwood Pharmaceuticals, Inc.'s yearly revenue has decreased 15.72% since last year from $351.41M to $296.15M, signaling decreasing performance

ROIC 57.85% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Ironwood Pharmaceuticals, Inc.'s 3-year revenue CAGR of -10.32% is negative, indicating declining revenue over the past 3 years

Ironwood Pharmaceuticals, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Ironwood Pharmaceuticals, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Ironwood Pharmaceuticals, Inc. is undervalued relative to its fair value price of 4.89 based on Discounted Cash Flow model

Ironwood Pharmaceuticals, Inc. has an earnings yield of 19.38%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Ironwood Pharmaceuticals, Inc. is overvalued relative to its fair value price of 2.15 based on EBITDA multiple model

Ironwood Pharmaceuticals, Inc. has an EV/EBITDA ratio of 10.02x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Ironwood Pharmaceuticals, Inc. is overvalued relative to its fair value price of 3.70 based on Earnings Fair Value model

Ironwood Pharmaceuticals, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Ironwood Pharmaceuticals, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Ironwood Pharmaceuticals, Inc. has a price-to-sales ratio of 1.72x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue